Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Condylomata Acuminata 10Uterine Cervical Neoplasms 8Papillomavirus Infections 4Vulvar Neoplasms 3Vaginal Neoplasms 3Uterine Cervical Dysplasia 1Penile Neoplasms 1Anus Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5fludarabine 3Vaccines, Synthetic 3Vaccines 3Papillomavirus Vaccines 3Cyclophosphamide 3pembrolizumab 2aflibercept 2trastuzumab deruxtecan 1lenvatinib 1Quality of Life 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Immunotherapy 1Ganciclovir 1Fentanyl 1Drug Therapy 1Carboplatin 1Biological Therapy 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Vulvar Neoplasms × Vaccines, Synthetic × Clear all
NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Recruiting
8,000 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT01245764 2018-11-14

GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Merck Sharp & Dohme LLC

Phase 3 Completed
250 enrolled 20 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
620 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡